

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

ABBVIE INC., ABBVIE LTD. and	)	
NEUROCRINE BIOSCIENCES, INC.,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. _____
	)	
ALKEM LABORATORIES LIMITED,	)	
HETERO LABS LIMITED, HETERO LABS	)	
LIMITED UNIT-V, HETERO USA INC.,	)	
LUPIN LIMITED, LUPIN	)	
PHARMACEUTICALS, INC., MSN	)	
LABORATORIES PRIVATE LTD., MSN	)	
LIFE SCIENCES PVT. LTD., MSN	)	
PHARMACEUTICALS INC., PRINSTON	)	
PHARMACEUTICAL INC., ZHEJIANG	)	
HUAHAI PHARMACEUTICAL CO., LTD.,	)	
SOLCO HEALTHCARE US, LLC., SANDOZ	)	
INC., SUN PHARMACEUTICAL	)	
INDUSTRIES LIMITED, TEVA	)	
PHARMACEUTICALS, INC., TEVA	)	
PHARMACEUTICAL INDUSTRIES LTD.,	)	
ZENARA PHARMA PRIVATE LIMITED and	)	
BIOPHORE INDIA PHARMACEUTICALS	)	
PRIVATE LTD.,	)	
	)	
Defendants.	)	

**SUPPLEMENTAL INFORMATION FOR PATENT CASES**  
**INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**  
as to Lupin Limited and Lupin Pharmaceuticals, Inc.

Plaintiffs hereby provide the information below with respect to the deadlines set forth in  
21 U.S.C. § 355(j):

Date Patentee(s) Received Notice:	September 19, 2022
Date NDA Holder Received Notice:	September 19, 2022
Date of Expiration of U.S. Patent No. 7,056,927:	September 10, 2024*
Date of Expiration of U.S. Patent No. 7,419,983:	July 6, 2024**

Date of Expiration of U.S. Patent No. 10,537,572: September 1, 2036

Date of Expiration of U.S. Patent No. 10,682,351: September 1, 2036

Date of Expiration of U.S. Patent No. 11,344,551: March 14, 2034

Hatch-Waxman Regulatory Exclusivity Deadline: January 23, 2026

\*The patent applicant has applied for extension of patent term of the '927 patent under 35 U.S.C. § 156 of 1,826 days. Accordingly, the '927 patent will expire on September 10, 2029, if granted the 1,826 days of patent term extension.

\*\*The patent applicant has applied for extension of patent term of the '983 patent under 35 U.S.C. § 156 of 1,826 days. Accordingly, the '983 patent will expire on July 6, 2029, if granted the 1,826 days of patent term extension.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

*/s/ Jeremy A. Tigan*

OF COUNSEL:

Jennifer H. Roscetti  
Danielle A. Duszczyszyn  
William B. Raich  
Constance P. Lee  
Ryan V. McDonnell  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP  
901 New York Avenue, NW  
Washington, DC 20001-4431  
(202) 408-4000

---

Jack B. Blumenfeld (#1014)  
Jeremy A. Tigan (#5239)  
Megan E. Dellinger (#5739)  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899  
(302) 658-9200  
jblumenfeld@morrisnichols.com  
jtigan@morrisnichols.com  
mdellinger@morrisnichols.com

*Attorneys for Plaintiffs AbbVie Inc., AbbVie Ltd.,  
and Neurocrine Biosciences, Inc.*

October 27, 2022